IRD
Opus Genetics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.16 EPS, $2.45M rev
Last earnings +1.2% on 2026-05-12
$4.00
▲ +7.53%$4.00▲ +321.05%
over 1Y
L $0.91EODHDH $5.75
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.5%
1W-2.0%
1M-3.4%
3M-8.0%
YTD+88.7%
1Y+321.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 20 analysts
Buy
Revenue grew 29.1% YoY; but unprofitable (net margin -349.3%).
Opus Genetics, Inc. shows $14.2M in FY2025 revenue (+29.1% YoY), a -349.3% net margin, and -323.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $589K | $39.9M | $19.0M | $11.0M | $14.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$22.7M | $18.2M | -$10.6M | -$62.1M | -$38.6M |
| Net income | -$56.7M | $17.9M | -$9.99M | -$57.5M | -$49.6M |
| Diluted EPS | -$3.82 | $0.87 | -$0.46 | -$2.15 | -$0.80 |
| Net margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$241M
EV / EBITDA—
EV / Sales17.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-17.4%
FCF yield-12.4%
Quality & risk
ROIC (est.)-185.1%
Free cash flow-$35.3M
Total debt$1.13M
Net cash$44.0M
Altman Z-Score-1.60 distress
Piotroski F-Score3/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+56.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-06-16
- 8-K Reg FD disclosure2026-06-16
- S-3 Shelf registration (potential raise)2026-06-05
- 8-K Earnings results2026-05-12
- 10-Q Quarterly report2026-05-12
- 8-K New financial obligation2026-04-24
- 8-K Shareholder vote2026-04-22
- S-3/A Shelf registration (potential raise)2026-04-21
- 8-K Officer / director change2026-04-07
Recent filings
all on EDGAR ↗424B2Filing2026-06-17open ↗8-KPeriod ending 2026-06-162026-06-16open ↗8-KPeriod ending 2026-06-162026-06-16open ↗EFFECTFiling2026-06-15open ↗S-3Filing2026-06-05open ↗SCHEDULE 13D/AFiling2026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗S-8Filing2026-05-14open ↗
Frequently asked
- Is Opus Genetics, Inc. (IRD) a buy?
- IRD currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 29.1% YoY; but unprofitable (net margin -349.3%).
- What is Opus Genetics, Inc.'s quality score?
- IRD scores 43.627450980392155/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001228627, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:18:40 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.